On October 1, 2020 Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon), reported that it will present new preliminary data from the Phase I/II TEM-GBM study of Temferon in patients affected with glioblastoma multiforme, at the 4th Virtual Annual Genetic Medicines Conference, hosted by Chardan on 5th and 6th of October 2020 (Press release, Genenta Science, OCT 1, 2020, View Source [SID1234567855]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pierluigi Paracchi, Chairman and Chief Executive Officer at Genenta Science and Dr. Carlo Russo, Chief Medical Officer and Head of Development, will present the data along with an overview of the company’s pipeline and development of Temferon in two solid tumor indications.

Presentation Details:
Date: Tuesday, October 6
Time (EDT): starting from 2:30pm

Registration at: View Source